Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Abbott’s FreeStyle Libre System Approved for Use in Pregnancy

Posted on: 07 Aug 17

LONDON, Aug. 07, 2017 — Today Abbott has announced that its FreeStyle Libre system has been CE marked for use in pregnant women  with Type 1 or Type 2 diabetes, and gestational diabetes.  The system, which is clinically proven to be accurate and safe for use during pregnancy[i], allows pregnant women to monitor their glucose levels without routine [ii] finger prick testing through the use of a small round sensor worn on the back of the upper arm.

Approximately 7.5 percent of all pregnant women have Type 1 or Type 2 diabetes and one in seven women will develop gestational diabetes during their pregnancy. [iii]  In order to ensure a healthy pregnancy, women with diabetes need to frequently monitor their glucose levels [iv], as they are especially at risk of both hyperglycaemia and hypoglycaemia.[v]

The FreeStyle Libre system enables a person with diabetes to check their glucose through the use of a small, discreet sensor, which is approximately the size of a £2 coin and automatically measures glucose for up to 14 days. In the IMPACT clinical trial [vi],  users of the FreeStyle Libre system spent less time in hypoglycemia, including at night, without increasing HbA1c compared to SMBG. Data from real-world use[vii] also shows that higher rates of scanning with the FreeStyle Libre system were found to be strongly associated with improved glucose control.

In addition to improved control, checking glucose with the FreeStyle Libre system during pregnancy has been found to be less stressful (98%), less painful (100%), easier to use (94%), and more discreet (95%) than other methods such as finger prick testing.[i]

“The approval of the FreeStyle Libre product for use during pregnancy will increase the quality of life for pregnant women while also helping them to more closely and effectively manage their diabetes,” said Dr Eleanor Scott, Senior Lecturer in Medicine, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds and Consultant in Diabetes and Endocrinology, Leeds Teaching Hospitals NHS Trust. “This is particularly true for women who have developed gestational diabetes and are managing a new condition while also dealing with all of the usual challenges of pregnancy.”


For more information, please visit



About Abbott

At Abbott, we’re committed to helping you live your best possible life through the power of health. For more than 125 years, we’ve brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life.


Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.


Connect with us at, on Facebook at and on Twitter @AbbottNews and @AbbottGlobal.  


Editor's Details

Mike Wood

Last updated on: 07/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.